$1.79 Billion is the total value of Flagship Pioneering Inc.'s 19 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 11.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Sell | Moderna Inc | $995,047,000 | +6.3% | 50,871,524 | -13.5% | 55.62% | +8.6% |
| RUBY | Rubius Therapeutics Inc | $363,817,000 | +21.0% | 38,296,526 | 0.0% | 20.34% | +23.7% | |
| DNLI | Sell | Denali Therapeutics Inc | $139,016,000 | +13.3% | 7,980,263 | -0.3% | 7.77% | +15.8% |
| KLDO | Kaleido Biosciences Inc | $87,151,000 | -33.3% | 17,360,710 | 0.0% | 4.87% | -31.9% | |
| MCRB | Seres Therapeutics Inc | $74,423,000 | -14.0% | 21,571,764 | 0.0% | 4.16% | -12.1% | |
| EVLO | Evelo Biosciences Inc | $74,027,000 | -33.4% | 18,233,403 | 0.0% | 4.14% | -32.0% | |
| AXLA | Axcella Health Inc | $35,081,000 | -29.2% | 8,748,414 | 0.0% | 1.96% | -27.6% | |
| SYRS | Syros Pharmaceuticals Inc | $20,305,000 | -33.4% | 2,938,494 | 0.0% | 1.14% | -32.0% | |
| TMDX | Sell | TransMedics Group Inc | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| QTRX | Exit | Quanterix Corp | $0 | – | 0 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.